How HAL compare to other biotherapeutics
- Enhanced pharmacokinetics of peptide drugs
- May incorporate polymer technology
- Oral, pulmonary or topical delivery could be possible
- More readily formulated than antibodies
- HAL are not prone to proteolytic destruction
- Low or no side effects
- HAL are less immunogenic
- Production costs
- Strong IP Position
- New class of drugs to address markets